Next Article in Journal
Melanoma as Subsequent Primary Malignancy in Hematologic Cancer Survivors—A Literature Review
Previous Article in Journal
Correlation between Anterior Cruciate Ligament–Return to Sport after Injury Score at 6 Months after Anterior Cruciate Ligament Reconstruction and Mid-Term Functional Test Results: An Observational Study at 5-Year Follow-Up
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JCM
Volume 13
Issue 15
10.3390/jcm13154500
jcm-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Effects of Psychiatric Comorbidities on the Prognosis of New-Onset Pediatric Epilepsy: A Retrospective Nationwide Cohort Study

by
Jooyoung Lee
1,
Arum Choi
2 and
Sukil Kim
2,*
1
Department of Pediatrics, Eunpyeong St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul 03312, Republic of Korea
2
Department of Preventive Medicine and Public Health, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2024, 13(15), 4500; https://doi.org/10.3390/jcm13154500
Submission received: 7 July 2024 / Revised: 24 July 2024 / Accepted: 31 July 2024 / Published: 1 August 2024
(This article belongs to the Section Clinical Neurology)
Browse Figures
Versions Notes

Abstract

:
Background/Objectives: To determine the impact of psychiatric disorders on epilepsy treatment outcomes and healthcare utilization in children with epilepsy (CWE) based on the presence or timing of the onset of psychiatric disorders. Methods: This retrospective controlled study enrolled children (age < 18 years) with newly diagnosed epilepsy into four groups stratified by the presence and timing of the onset of psychiatric disorders (None: no psychiatric disorders; Before: psychiatric disorders only preceding the epilepsy diagnosis; After: new psychiatric disorders diagnosed only after the epilepsy diagnosis; Mixed: different psychiatric disorders diagnosed both before and after epilepsy diagnosis) and compared the intergroup differences in epilepsy treatment outcomes and healthcare utilization. Results: Among the CWE (n = 37,678), 13,285 (35.26%) had comorbid psychiatric disorders. The After (n = 7892), Mixed (n = 3105), and Before (n = 2288) groups had significantly longer treatment periods than those in the None group (p < 0.001). Compared with the None group, the remaining groups had significantly higher frequencies of outpatient visits, emergency room visits, and admissions and higher rates of status epilepticus and drug-resistant epilepsy (p < 0.001, respectively), with higher odds ratios [95% confidence interval] for status epilepticus (2.92 [2.68–3.18]) and drug-resistant epilepsy (3.01 [2.85–3.17]) in the After group. Conclusions: Psychiatric comorbidities, diagnosed before and after epilepsy diagnosis, negatively affected the treatment outcomes. CWE without prior psychiatric disorders that were newly diagnosed during epilepsy treatment had the worst outcomes and the highest healthcare utilization rates.

1. Introduction

The lifetime prevalence of epilepsy is approximately 1%, and the incidence of epilepsy has a U-shaped distribution by age, with a notable incidence in pediatric patients [1,2]. Children with epilepsy (CWE) frequently present with physical and/or psychiatric disorders [3]. The prevalence of comorbid psychiatric disorders is between 23% and 77%, which is three to seven times higher than that in children without epilepsy [4,5,6,7,8]. In CWE, comorbid psychiatric disorders predominantly include attention-deficit hyperactivity disorder (ADHD), intellectual disability, behavior/emotional disorders, and autism [1,4,6,7]. Several studies have reported that psychiatric disorders increase seizure frequency by lowering the seizure threshold [9,10]. Anti-seizure medication (ASM) or specific types of epilepsy, such as temporal lobe epilepsy, can cause psychiatric disorders [11,12,13], with some studies reporting a bidirectional relationship between epilepsy and psychiatric disorders and the impact of psychiatric comorbidities on CWE. Lower rates of seizure freedom have been reported in CWE with than in those without psychiatric comorbidities [9,14,15]. Comorbid psychiatric conditions negatively affect academic achievement, hinder social adaptation, increase suicide risk, and collectively diminish long-term quality of life [7,16,17,18].
This study aimed to determine the prevalence of psychiatric comorbidities in CWE in South Korea and to evaluate the impact of these disorders on the treatment outcomes of epilepsy. We used a large national CWE sample while considering various factors, such as the incidence of status epilepticus and drug-resistant epilepsy (DRE), and healthcare utilization, including the frequency of admission and emergency room and outpatient visits. We analyzed the differences in prognosis based on the timing of psychiatric comorbidity onset.

2. Materials and Methods

2.1. Data Source

We used the health insurance claims data of the Health Insurance Review and Assessment Service (HIRA) in South Korea collected from 1 January 2007 to 31 December 2022. Korean National Health Insurance covers 98% of the overall population. The HIRA claims data include diagnosis, surgeries, treatments, and prescriptions [19].

2.2. Study Population: Inclusion and Exclusion Criteria

The participants were pediatric patients with epilepsy (age < 18 years) who were newly diagnosed between 1 January 2009 and 31 December 2018. Patients with epilepsy were defined as patients (1) with diagnostic codes corresponding to epilepsy (epilepsy [G40], status epilepticus [G41], and/or seizure [R568]) of the Korean Standard Classification of Diseases (KCD), which is a Korean modification of the International Statistical Classification of Disease and Related Health Problems 10th Revision; (2) who claimed insurance including epilepsy-related diagnostic codes at least twice more than 30 days apart, including inpatients and outpatients; and (3) who were prescribed at least one ASM for 180 days or more during 1 year from the index date, which is the first day with epilepsy-related diagnosis codes with at least one ASM prescription. The ASMs included carbamazepine, clobazam, clonazepam, ethosuximide, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, phenobarbital, phenytoin/fosphenytoin, pregabalin, primidone, rufinamide, topiramate, valproate/valproic acid, vigabatrin, zonisamide, and lacosamide. Febrile seizures (R560) were not considered in this study. Newly diagnosed patients with epilepsy were defined as those (1) meeting the criteria for patients with epilepsy and (2) without epilepsy-related diagnostic codes and ASM prescriptions during the 2-year lookback period from the index date. Children under 2 years of age were included in the study if they did not have an epilepsy-related diagnosis code and an ASM prescription between birth and the index date.

2.3. Definition of Psychiatric Disorder

The working definitions of patients with psychiatric disorders were those who used healthcare services more than twice between 1 January 2007 and 31 December 2021, with the same psychiatric diagnoses in the KCD: schizophrenia spectrum disorder and other psychotic disorders (F20–F29), bipolar disorder (F30 and F31), depressive disorder (F32 and F33), anxiety disorder (F40 and F41), obsessive–compulsive disorder (F42), post-traumatic stress disorder (F43), sleep disorder (F51), intellectual disability (F70–F79), communication disorder (F80), specific learning disorder (F81), autism spectrum disorder (F84), attention-deficit hyperactivity disorder (F90), oppositional defiant disorder/conduct disorder (F91 and F92), and tic disorder (F95).
New psychiatric disorders were defined as (1) meeting the criteria for psychiatric disorders and (2) psychiatric disorders diagnosed in patients without previous psychiatric disorders during the 2-year lookback period. For children under the age of 2 years, observation began at birth to determine whether they had been seen more than twice for the same psychiatric condition. The date of diagnosis of psychiatric disorders in patients judged to have a psychiatric disorder was the date when the diagnosis code was first entered.
Participants were classified into four groups according to the date of the diagnosis of psychiatric disorders compared to the index date as follows: None: no psychiatric disorders; Before: psychiatric disorders only preceding the epilepsy diagnosis; After: psychiatric disorders only after the epilepsy diagnosis; and Mixed: different psychiatric disorders diagnosed both before and after the epilepsy diagnosis. Psychiatric disorders diagnosed after the index date were limited to those diagnosed during the epilepsy treatment period, whereas cases of psychiatric disorders diagnosed after epilepsy treatment had ended were not considered.

2.4. Variables

The treatment duration of epilepsy was defined as the period from the index date to the last date of ASM administration. A patient was considered to be on continuous medication if an alternative medication was prescribed within 30 days of the last administration of the previous prescription. Treatment discontinuation was defined as not taking medication for at least six consecutive months from the date of the last medication administration. We identified the number of patients in each group with a primary or secondary diagnosis of status epilepticus (G41) and the number of outpatient and emergency department visits with epilepsy-related diagnoses (G40, G41, and R560) during the treatment period. DRE was defined as a condition wherein a patient simultaneously received three or more ASMs with distinct components in a single prescription or that included diagnosis codes related to intractable epilepsy.

2.5. Study Outcome

This study aimed to determine the proportion of CWE in South Korea with comorbid psychiatric disorders and to evaluate the impact of these disorders on epilepsy treatment by comparing the treatment duration of epilepsy, incidence of status epilepticus and DRE, and number of outpatient and emergency department visits according to the presence and timing of the onset of psychiatric disorders.

2.6. Statistical Analysis

We used Pearson’s chi-square test to compare the proportions of categorical variables. Owing to the non-normal distribution of the data, we used the Kruskal–Wallis rank sum test to compare the means across the four groups (i.e., None, Before, After, and Mixed). We used Kaplan–Meier and Cox regression analyses, adjusted for age and sex, to examine intergroup differences in the treatment duration for epilepsy. To evaluate the impact of psychiatric disorders on the treatment for epilepsy, relative to the index date of the epilepsy diagnosis, we performed logistic regression analyses for binary outcomes (e.g., presence of status epilepticus, drug-resistant epilepsy) and Poisson regression analyses for the frequency (e.g., number of outpatient visits, ER visits, admissions). We used an alpha level of 0.05 for all statistical tests. Exact p-values are reported, and p-values less than 0.001 are reported as p < 0.001. SAS Enterprise Guide 9.4.2® (SAS Institute Inc., Cary, NC, USA) and R (version 3.5.1; R Foundation for Statistical Computing, Vienna, Austria) were used for the statistical analysis.

3. Results

3.1. Participants with Epilepsy and Psychiatric Disorder

From 1 January 2009 to 31 December 2018, 40,562 patients aged <18 years were newly diagnosed with epilepsy and treated with ASM, and 37,678 of these patients remained after applying a 2-year lookback period for psychiatric disorders (Figure 1). A total of 13,285 patients (37.73%) had one or more psychiatric disorders, and the After group had the highest proportion of patients among the groups with psychiatric disorders (59.41%). The total number of patients diagnosed with one or more psychiatric disorders after the epilepsy index date was 10,997, representing approximately a quarter of all CWE. The distribution and type of psychiatric disorders that occurred before and after the index date are shown in Table 1. Patients diagnosed with a psychiatric disorder before the index date had the highest rates of ADHD, followed by anxiety disorder, followed by depressive disorder, and patients diagnosed with a psychiatric disorder after the index date had the highest rates of anxiety disorder, followed by depressive disorder, followed by bipolar disorder. The proportions of males and females diagnosed with each psychiatric disorder are presented in Supplementary Table S1. Except for post-traumatic stress disorder, the proportion of males was significantly higher than that of females for the psychiatric disorders.

3.2. Characteristics of the Four Groups

The characteristics of each group are shown in Table 2. All groups had a higher proportion of males than females. The age group with the highest proportion was 5–13 years (42.45%). There were differences in the distribution of groups according to age. The highest proportion of patients in the None group was <1 year old (73.83%), and the lowest proportion was 13–18 years old (56.83%). Patients aged <1 year comprised the highest proportion of patients in the After group (25.15%). Patients aged 13–18 years comprised the highest proportion of those diagnosed with one or more new psychiatric disorders after being diagnosed with epilepsy (After + Mixed group = 35.65%).

3.3. Intergroup Differences in Treatment Outcomes and Healthcare Utilization

The None group had the shortest treatment duration (5.36 ± 3.59 years, adjusted hazard ratio [HR] = 1, reference), whereas the After group had the longest treatment duration (8.31 ± 3.65 years, adjusted HR = 0.37, 95% confidence interval [CI] = 0.35–0.38, p < 0.001), followed by the Mixed group (6.54 ± 3.43, adjusted HR = 0.62 95% CI = 0.59–0.66, p < 0.001) and Before group (5.59 ± 3.33, adjusted HR = 0.79, 95% CI = 0.75–0.84, p < 0.001) (Figure 2). The number of outpatient visits, emergency room visits, and admissions was approximately double in the After group compared to those in the None group. The total number of medications was the lowest in the None group (2.31 ± 1.83) and the highest in the After group (4.05 ± 2.83), followed by the Mixed (2.88 ± 2.07) and Before (2.46 ± 1.93) groups. Patients diagnosed with status epilepticus and those categorized as DRE had the highest rates in the After group (14.04% and 55.61%, respectively), which were 2.53 and 1.80 times those of the None group.

3.4. Regression Analysis on the Healthcare Utilization and Clinical Characteristics for Epilepsy

The associations between the clinical characteristics and healthcare utilization and the presence and timing of the onset of psychiatric disorders are presented in Table 3 and Table 4. The odds ratio (OR) or prevalence ratio (PR) for all clinical characteristics and healthcare utilization was greater than 1.0 in the Before, After, and Mixed groups compared to the None group. For all variables, the strongest association was found in the After group, with a particularly high OR for status epilepticus (PR = 2.92, 95% CI = 2.68–3.18) and DRE (PR = 3.01, 95% CI = 2.85–3.17). Compared to the Mixed group, the After group showed higher correlations for all clinical characteristic variables, with a particularly high PR value for DRE (PR = 1.89, 95% CI = 1.73–2.06), while the Before group had a lower correlation for the total number of medications and DRE (Table 5). However, the Before group did not differ significantly from the Mixed group for status epilepticus.

4. Discussion

This large-scale retrospective controlled study using 10-year nationwide data classified psychiatric diseases based on the timing of onset and confirmed the association of psychiatric comorbidities with both treatment response and healthcare utilization in CWE. In this study, we confirmed that CWE co-occurring with psychiatric disorders had worse treatment outcomes for epilepsy than CWE without psychiatric disorders. In particular, CWE who were newly diagnosed with a psychiatric disorder during epilepsy treatment, especially those who had not been diagnosed with a psychiatric disorder before an epilepsy diagnosis, had worse treatment outcomes and more healthcare utilization than the other groups.
Herein, we explain the rationale behind the methodological approach used in our study. To identify patients with epilepsy with sufficient reliability using claims data, we checked not only the number of outpatient visits, including emergency room and admissions with epilepsy-related diagnosis codes, but also medication use [20,21,22,23,24]. Validation studies for all psychiatric conditions in insurance claims data were difficult to find, and many studies have been conducted using disparate methods [4,16,25,26,27,28,29,30]. Using these as guides, to increase the reliability of psychiatric diagnoses, we defined a person with a psychiatric diagnosis if they had at least two visits (admission, outpatient, or emergency room visits) with the same diagnosis code (KCD code: F00-99) as a primary or additional diagnosis. While including medication in the definition of psychiatric diagnosis would have increased the specificity, we did not account for medication status because Korean parents are reluctant to have their children diagnosed with a psychiatric disorder and want to avoid medication as much as possible, which could result in undue under-representation of psychiatric disorders. Given that younger patients with epilepsy are more likely to develop psychiatric disorders during the observation period, we sought to determine the impact of psychiatric disorders on epilepsy treatment by identifying only the psychiatric disorders that occurred during epilepsy treatment after the index date. As DREs are not assigned to the ICD-10 or KCD, additional definitions are needed. According to the International League Against Epilepsy definition, DRE is characterized by a failure to achieve seizure-free status despite the use of two ASMs as a monotherapy or combination therapy [31]. However, insurance claims data do not allow us to determine exactly why the medication was changed or added. Therefore, various methods have been used to define DRE in studies using claims or administrative data [32,33,34,35]. As the most sensitive definition of DRE, we defined DRE as having concurrent prescriptions for three or more ASMs or a diagnosis code related to intractable epilepsy [32].
The proportion of CWE in South Korea with at least one comorbid psychiatric disorder is approximately 40%, which is similar to the proportion in other countries [4,7,36]. In our study, psychiatric disorders were 2.04 times more likely to develop during epilepsy treatment than when epilepsy developed in patients previously diagnosed with a psychiatric disorder. The rates of each psychiatric disorder in CWE vary across studies [4,9,16]. In the present study, the most common psychiatric disorders before and after epilepsy diagnosis were anxiety disorder, depressive disorder, and ADHD (Table 1). ADHD was the most diagnosed psychiatric disorder prior to the diagnosis of epilepsy, whereas anxiety disorders were the most common following the initiation of epilepsy treatment. In our study, we found a higher proportion of males than females for almost all psychiatric disorders. For disorders such as ADHD, autism, learning disorders, and tic disorders, which are known to have a higher prevalence among males in the general population, the proportion of males in our study group exceeded 60%. However, mood disorders, which are typically more common in females in the general population, showed a higher prevalence among males in our study group, which indicates a difference. However, the group with post-traumatic stress disorder had a higher proportion of females, which is consistent with the prevalence in the general population [37,38].
Furthermore, CWE with psychiatric disorders had worse outcomes, such as a longer treatment duration of epilepsy and a higher rate of developing status epilepticus or refractory epilepsy in this study. This finding is consistent with previous studies that have shown lower rates of seizure freedom in patients with comorbid psychiatric conditions [9,14,15]. Comorbid psychiatric disorders may themselves contribute to refractory epilepsy, or conversely, refractory epilepsy may lead to increased medication use, which in turn may increase the incidence of psychiatric disorders [3,10].
This study found that CWE with psychiatric disorders had significantly higher rates of all healthcare utilization than CWE without psychiatric disorders, as reported in previous studies [9,39] and is an expected outcome of increased healthcare utilization associated with a relatively poor prognosis. Similarly, in our study, the highest healthcare utilization was observed in children with psychiatric disorders after epilepsy diagnosis, and these children had the worst outcomes.
We went beyond merely ascertaining the impact of comorbid psychiatric disorders on epilepsy treatment to evaluating the impact of the timing of the onset of psychiatric disorders. As shown in Table 5, even among CWE with comorbid psychiatric disorders, there were differences in treatment responses based on the timing of their onset. The presence of a psychiatric disorder prior to the diagnosis of epilepsy had less of an association with treatment outcome if no additional psychiatric disorder developed during epilepsy treatment. In contrast, patients who developed a psychiatric disorder during treatment had the worst prognosis, especially if a new psychiatric disorder occurred in patients who did not have a psychiatric disorder before epilepsy treatment. This may be due to differences in the types of psychiatric disorders that occurred before and after epilepsy. However, if these findings were simply because psychiatric disorders had a negative impact on epilepsy treatment, or if they were due to differences in the types of psychiatric disorders that occurred, we would expect to see the worst outcomes in patients who had psychiatric disorders before epilepsy and who developed a new psychiatric disorder after epilepsy (Mixed group). However, our findings contradicted this expectation, with the findings showing the worst treatment prognosis in patients who developed a new psychiatric disorder in the absence of a previous psychiatric disorder (After group). Even if the increased use of ASM in patients with refractory epilepsy and the subsequent development of psychiatric disorders as a side effect could explain the worse treatment outcome in patients who developed psychiatric disorders after epilepsy, explaining the difference between the After and Mixed groups is difficult. Ultimately, we can infer that these results are the result of differences in clinicians being mindful of the development of psychiatric disorders in their patients. Children with pre-existing psychiatric conditions are more likely to develop additional psychiatric conditions. Early detection is associated with timely intervention and better outcomes in psychiatric disorders [26,40]. Therefore, children with pre-existing psychiatric conditions are likely to receive continuous monitoring, which increases the likelihood of early detection and timely treatment of additional psychiatric disorders. In contrast, in patients without pre-existing psychiatric disorders, the lack of ongoing attention to and assessment of psychiatric symptoms is likely to result in a delay in recognizing symptoms; therefore, a longer interval before diagnosis and treatment may have a negative impact on the treatment of epilepsy. Thus, awareness and constant attention to the possibility of psychiatric disorders in CWE are necessary. Furthermore, informing patients and/or caregivers about the possibility of psychiatric disorders, the need for vigilance against the stigma of psychiatric disorders, and the need to report suspicious symptoms early are important to improving the prognosis of epilepsy treatment. Further research is needed on the impact of the timing of onset of psychiatric illness on the prognosis of epilepsy treatment.
This study has several limitations. First, this study was conducted using insurance claims data, which limited the ability to verify each patient’s symptoms and test results. Therefore, it was not possible to reflect differences in treatment outcomes based on the frequency of seizures or the severity of psychiatric symptoms during epilepsy treatment. Second, adherence to ASM may have an impact on the prognosis of epilepsy treatment [41]; however, these data are unavailable in claims data. Therefore, its impact could not be assessed. Third, we were unable to identify epilepsy recurrences for which no diagnostic code was assigned. Therefore, we were unable to determine whether psychiatric disorders were associated with epilepsy recurrence. Finally, this study identified the impact of psychiatric disorders as a whole, and the impact of each psychiatric disorder on epilepsy treatment is difficult to determine. Future studies should explore the effects of individual psychiatric disorders. Furthermore, it is necessary to analyze the difference in the treatment outcomes for epilepsy based on the age at which psychiatric disorders are diagnosed and to determine the specific psychiatric-disorder-stratified treatment outcomes in epilepsy.

5. Conclusions

Comorbid psychiatric disorders negatively impact epilepsy treatment and are associated with increased healthcare utilization. A poorer treatment response was observed in children with a newly diagnosed psychiatric disorder after the diagnosis of epilepsy. Among these patients, the worst outcomes and highest healthcare utilization rates were noted in children without a psychiatric disorder before the diagnosis of epilepsy. To reduce the impact of psychiatric disorders on the treatment of epilepsy and to improve the treatment prognosis of epilepsy, the ongoing assessment of psychiatric disorders during epilepsy treatment is necessary, and management to prevent psychiatric disorders in CWE may help improve prognosis.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/jcm13154500/s1, Table S1: Sex-specific Proportions of Psychiatric Disorders in Children with Epilepsy.

Author Contributions

Conceptualization, J.L. and S.K.; methodology, J.L., S.K., and A.C.; formal analysis, A.C.; investigation, A.C.; resources, S.K.; data curation, A.C.; writing—original draft preparation, J.L.; writing—review and editing, J.L., A.C., and S.K.; supervision, S.K. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by the Research Institute of Medical Science at Eunpyeong St. Mary’s Hospital, Catholic University of Korea. The funders/sponsors had no role in the design or conduct of this study. [funding number: EMDRF-2024-06].

Institutional Review Board Statement

This study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board of Eunpyeong Saint Mary’s Hospital (approval No. PC23ZISI0116, approval date: 13 July 2023). Study data were obtained from the HIRA database (accession No. M20230914001). Patient consent was waived due to the use of anonymized data provided by the Health Insurance Review and Assessment Service.

Informed Consent Statement

This study used anonymized data, and therefore patient consent was waived. This waiver was approved by the relevant ethics committee.

Data Availability Statement

We obtained health insurance claims data from HIRA for use in our research, and these data are accessible to anyone through approval from the institution. The data provided by HIRA were anonymized and stripped of personally identifiable information before being made available.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Russ, S.A.; Larson, K.; Halfon, N. A national profile of childhood epilepsy and seizure disorder. Pediatrics 2012, 129, 256–264. [Google Scholar] [CrossRef]
  2. Bartolini, E.; Ferrari, A.R.; Lattanzi, S.; Pradella, S.; Zaccara, G. Drug-resistant epilepsy at the age extremes: Disentangling the underlying etiology. Epilepsy Behav. 2022, 132, 108739. [Google Scholar] [CrossRef]
  3. Keezer, M.R.; Sisodiya, S.M.; Sander, J.W. Comorbidities of epilepsy: Current concepts and future perspectives. Lancet Neurol. 2016, 15, 106–115. [Google Scholar] [CrossRef]
  4. Aaberg, K.M.; Bakken, I.J.; Lossius, M.I.; Lund Søraas, C.; Håberg, S.E.; Stoltenberg, C.; Surén, P.; Chin, R. Comorbidity and childhood epilepsy: A nationwide registry study. Pediatrics 2016, 138, e20160921. [Google Scholar] [CrossRef] [PubMed]
  5. Hackett, R.; Hackett, L.; Bhakta, P. Psychiatric disorder and cognitive function in children with epilepsy in Kerala, South India. Seizure 1998, 7, 321–324. [Google Scholar] [CrossRef] [PubMed]
  6. Plioplys, S.; Dunn, D.W.; Caplan, R. 10-year research update review: Psychiatric problems in children with epilepsy. J. Am. Acad. Child Adolesc. Psychiatry 2007, 46, 1389–1402. [Google Scholar] [CrossRef]
  7. Salpekar, J.A.; Mula, M. Common psychiatric comorbidities in epilepsy: How big of a problem is it? Epilepsy Behav. 2019, 98, 293–297. [Google Scholar] [CrossRef]
  8. Tellez-Zenteno, J.F.; Patten, S.B.; Jetté, N.; Williams, J.; Wiebe, S. Psychiatric comorbidity in epilepsy: A population-based analysis. Epilepsia 2007, 48, 2336–2344. [Google Scholar] [CrossRef]
  9. Åndell Jason, E. Neurodevelopmental and psychiatric comorbidities negatively affect outcome in children with unprovoked seizures-a non-systematic review. Acta Paediatr. 2021, 110, 2944–2950. [Google Scholar] [CrossRef]
  10. Hesdorffer, D.C.; Ishihara, L.; Mynepalli, L.; Webb, D.J.; Weil, J.; Hauser, W.A. Epilepsy, suicidality, and psychiatric disorders: A bidirectional association. Ann. Neurol. 2012, 72, 184–191. [Google Scholar] [CrossRef]
  11. Mula, M.; Monaco, F. Antiepileptic drugs and psychopathology of epilepsy: An update. Epileptic Disord. 2009, 11, 1–9. [Google Scholar] [CrossRef] [PubMed]
  12. Mula, M.; Trimble, M.R.; Lhatoo, S.D.; Sander, J.W.A.S. Topiramate and psychiatric adverse events in patients with epilepsy. Epilepsia 2003, 44, 659–663. [Google Scholar] [CrossRef] [PubMed]
  13. Sanchez-Gistau, V.; Pintor, L.; Sugranyes, G.; Baillés, E.; Carreño, M.; Donaire, A.; Boget, T.; Setoain, X.; Bargalló, N.; Rumia, J. Prevalence of interictal psychiatric disorders in patients with refractory temporal and extratemporal lobe epilepsy in Spain. A comparative study. Epilepsia 2010, 51, 1309–1313. [Google Scholar] [CrossRef] [PubMed]
  14. Jason, E.Å.; Tomson, T.; Carlsson, S.; Tedroff, K.; Åmark, P. Neurodevelopmental comorbidities and seizure control 24 months after a first unprovoked seizure in children. Epilepsy Res. 2018, 143, 33–40. [Google Scholar] [CrossRef] [PubMed]
  15. Tsubouchi, Y.; Tanabe, A.; Saito, Y.; Noma, H.; Maegaki, Y. Long-term prognosis of epilepsy in patients with cerebral palsy. Dev. Med. Child Neurol. 2019, 61, 1067–1073. [Google Scholar] [CrossRef] [PubMed]
  16. Baca, C.B.; Vickrey, B.G.; Caplan, R.; Vassar, S.D.; Berg, A.T. Psychiatric and medical comorbidity and quality of life outcomes in childhood-onset epilepsy. Pediatrics 2011, 128, e1532–e1543. [Google Scholar] [CrossRef] [PubMed]
  17. Camfield, C.S.; Camfield, P.R. Long-term social outcomes for children with epilepsy. Epilepsia 2007, 48, 3–5. [Google Scholar] [CrossRef] [PubMed]
  18. Christensen, J.; Vestergaard, M.; Mortensen, P.B.; Sidenius, P.; Agerbo, E. Epilepsy and risk of suicide: A population-based case-control study. Lancet Neurol. 2007, 6, 693–698. [Google Scholar] [CrossRef]
  19. Kim, L.; Kim, J.A.; Kim, S. A guide for the utilization of Health Insurance Review and Assessment Service National Patient Samples. Epidemiol. Health 2014, 36, e2014008. [Google Scholar] [CrossRef]
  20. Han, S.H.; Lee, H.; Shin, J.Y.; Moon, H.J.; Lee, S.Y. Real-world prescribing trends of valproate in women with epilepsy in Korea. Epilepsy Behav. 2021, 115, 107700. [Google Scholar] [CrossRef]
  21. Jang, Y.; Lee, H.S.; Kim, M.S.; Lee, J.; Jung, K.Y. Anti-seizure medication prescription in epilepsy patients in South Korea: A seven-year population-based retrospective cohort study. Seizure 2023, 109, 70–76. [Google Scholar] [CrossRef]
  22. Lee, S.Y.; Chung, S.E.; Kim, D.W.; Eun, S.H.; Kang, H.C.; Cho, Y.W.; Yi, S.D.; Kim, H.D.; Jung, K.Y.; Cheong, H.K.; et al. Estimating the prevalence of treated epilepsy using administrative health data and its validity: ESSENCE Study. J. Clin. Neurol. 2016, 12, 434–440. [Google Scholar] [CrossRef]
  23. Reid, A.Y.; St Germaine-Smith, C.; Liu, M.; Sadiq, S.; Quan, H.; Wiebe, S.; Faris, P.; Dean, S.; Jetté, N. Development and validation of a case definition for epilepsy for use with administrative health data. Epilepsy Res. 2012, 102, 173–179. [Google Scholar] [CrossRef]
  24. Tu, K.; Wang, M.; Jaakkimainen, R.L.; Butt, D.; Ivers, N.M.; Young, J.; Green, D.; Jetté, N. Assessing the validity of using administrative data to identify patients with epilepsy. Epilepsia 2014, 55, 335–343. [Google Scholar] [CrossRef]
  25. Houghton, R.; Ong, R.C.; Bolognani, F. Psychiatric comorbidities and use of psychotropic medications in people with autism spectrum disorder in the United States. Autism Res. 2017, 10, 2037–2047. [Google Scholar] [CrossRef]
  26. Kim, S.W.; Kim, J.K.; Jhon, M.; Lee, H.J.; Kim, H.; Kim, J.W.; Lee, J.Y.; Kim, J.M.; Shin, I.S. Mindlink: A stigma-free youth-friendly community-based early-intervention centre in Korea. Early Interv. Psychiatry 2021, 15, 1389–1394. [Google Scholar] [CrossRef]
  27. Ogilvie, J.M.; Tzoumakis, S.; Allard, T.; Thompson, C.; Kisely, S.; Stewart, A. Prevalence of psychiatric disorders for Indigenous Australians: A population-based birth cohort study. Epidemiol. Psychiatr. Sci. 2021, 30, e21. [Google Scholar] [CrossRef]
  28. Rodrigues, R.; MacDougall, A.G.; Zou, G.; Lebenbaum, M.; Kurdyak, P.; Li, L.; Shariff, S.Z.; Anderson, K.K. Involuntary hospitalization among young people with early psychosis: A population-based study using health administrative data. Schizophr. Res. 2019, 208, 276–284. [Google Scholar] [CrossRef]
  29. van Fenema, E.; Giltay, E.; van Noorden, M.; van Hemert, A.; Zitman, F. Assessing adherence to guidelines with administrative data in psychiatric outpatients. J. Eval. Clin. Pract. 2017, 23, 5–13. [Google Scholar] [CrossRef]
  30. Wagner, C.J.; Metzger, F.G.; Sievers, C.; Marschall, U.; L’hoest, H.; Stollenwerk, B.; Stock, S. Depression-related treatment and costs in Germany: Do they change with comorbidity? A claims data analysis. J. Affect. Disord. 2016, 193, 257–266. [Google Scholar] [CrossRef]
  31. Kwan, P.; Arzimanoglou, A.; Berg, A.T.; Brodie, M.J.; Allen Hauser, W.; Mathern, G.; Moshé, S.L.; Perucca, E.; Wiebe, S.; French, J. Definition of drug resistant epilepsy: Consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia 2010, 51, 1069–1077. [Google Scholar] [CrossRef]
  32. Hill, C.E.; Lin, C.C.; Terman, S.W.; Rath, S.; Parent, J.M.; Skolarus, L.E.; Burke, J.F. Definitions of drug-resistant epilepsy for administrative claims data research. Neurology 2021, 97, e1343–e1350. [Google Scholar] [CrossRef]
  33. Strzelczyk, A.; Griebel, C.; Lux, W.; Rosenow, F.; Reese, J.P. The burden of severely drug-refractory epilepsy: A comparative longitudinal evaluation of mortality, morbidity, resource use, and cost using German health insurance data. Front. Neurol. 2017, 8, 712. [Google Scholar] [CrossRef]
  34. Sullivan-Baca, E.; Rehman, R.; Towne, A.R.; Haneef, Z. Psychiatric co-morbidity of drug-resistant epilepsy in Veterans. Epilepsy Behav. 2023, 139, 109059. [Google Scholar] [CrossRef]
  35. Teneralli, R.E.; Cepeda, M.S.; Kern, D.M.; Novak, G.P. Individuals who develop drug-resistant epilepsy within a year after initial diagnosis have higher burden of mental and physical diseases one-year prior to epilepsy diagnosis as compared to those whose seizures were controlled during the same interval. Epilepsy Behav. 2021, 123, 108243. [Google Scholar] [CrossRef]
  36. Christensen, J.; Dreier, J.W.; Sun, Y.; Linehan, C.; Tomson, T.; Marson, A.; Forsgren, L.; Granbichler, C.A.; Trinka, E.; Illiescu, C.; et al. Estimates of epilepsy prevalence, psychiatric co-morbidity and cost. Seizure 2023, 107, 162–171. [Google Scholar] [CrossRef]
  37. Swaab, D.F.; Bao, A.-M. Sex differences in stress-related disorders: Major depressive disorder, bipolar disorder, and posttraumatic stress disorder. Handb. Clin. Neurol. 2020, 175, 335–358. [Google Scholar] [CrossRef]
  38. Bölte, S.; Marschik, P.B.; Williams, Z.J.; Lai, M.-C.; Gallagher, L.; Neufeld, J. Sex and gender in neurodevelopmental conditions. Nat. Rev. Neurol. 2023, 19, 136–159. [Google Scholar] [CrossRef]
  39. Chuah, A.; Ding, K.; Morgado, A.; McCreary, M.; Zuberi, F.; Agostini, M.; Doyle, A. Effects of psychiatric comorbidities in persons with epilepsy on recurrent emergency department visits. Epilepsy Behav. 2022, 136, 108909. [Google Scholar] [CrossRef]
  40. Hennig, T.; Jaya, E.S.; Koglin, U.; Lincoln, T.M. Associations of attention-deficit/hyperactivity and other childhood disorders with psychotic experiences and disorders in adsolescence. Eur. Child Adolesc. Psychiatry 2017, 26, 421–431. [Google Scholar] [CrossRef]
  41. Lee, Y.K.; Ah, Y.M.; Choi, Y.J.; Cho, Y.S.; Kim, K.J.; Lee, J.Y. Antiepileptic drug adherence and persistence in children with epilepsy attending a large tertiary care Children’s Hospital. Epileptic Disord. 2016, 18, 408–417. [Google Scholar] [CrossRef] [PubMed]
Jcm 13 04500 g001
Figure 1. Flowchart depicting the enrollment of the study population. ASM, anti-seizure medication.
Figure 1. Flowchart depicting the enrollment of the study population. ASM, anti-seizure medication.
Jcm 13 04500 g001
Jcm 13 04500 g002
Figure 2. Kaplan–Meier plots showing the proportion of patients who received treatment after the index date. The proportion of patients treated with anti-seizure medication at different time periods from the index date (Time 0) is shown for each group. The solid lines show the unadjusted data. Dotted lines show the data adjusted for age and sex. HR, hazard ratio; CI, confidence interval.
Figure 2. Kaplan–Meier plots showing the proportion of patients who received treatment after the index date. The proportion of patients treated with anti-seizure medication at different time periods from the index date (Time 0) is shown for each group. The solid lines show the unadjusted data. Dotted lines show the data adjusted for age and sex. HR, hazard ratio; CI, confidence interval.
Jcm 13 04500 g002
Table 1. The distribution and type of psychiatric conditions occurring before and after the index date.
Table 1. The distribution and type of psychiatric conditions occurring before and after the index date.
Before Index DateAfter Index DateTotal
Schizophrenia spectrum disorder and other psychotic disorders (F20 to F29)451 (1.35)1483 (4.44)1934 (5.79)
Bipolar disorder (F30 and F31)490 (1.47)2687 (8.05)3177 (9.51)
Depressive disorder (F32 and F33)1423 (4.26)3472 (10.4)4895 (14.66)
Anxiety disorder (F40 and F41)1434 (4.29)4317 (12.93)5751 (17.22)
Obsessive–compulsive disorder (F42)116 (0.35)357 (1.07)473 (1.42)
Post-traumatic stress disorder (F43)399 (1.19)804 (2.41)1203 (3.60)
Sleep disorder (F51)191 (0.57)1108 (3.32)1299 (3.89)
Intellectual disability (F70 to F79)1193 (3.57)2782 (8.33)3975 (11.9)
Communication disorder (F80)859 (2.57)825 (2.47)1684 (5.04)
Specific learning disorder (F81)84 (0.25)171 (0.51)255 (0.76)
Autism spectrum disorder (F84)996 (2.98)1066 (3.19)2062 (6.17)
Attention-deficit hyperactivity disorder (F90)1761 (5.27)2494 (7.47)4255 (12.74)
Oppositional defiant disorder/conduct disorder (F91 and F92)352 (1.05)767 (2.30)1119 (3.35)
Tic disorder (F95)574 (1.72)739 (2.21)1313 (3.93)
Data are presented as the frequency (proportion). Proportions were calculated from the total number of participants in each category. The index date denotes the date of the first epilepsy-related diagnosis code with at least one ASM prescription.
Table 2. Participant characteristics stratified by the presence and timing of diagnosis of psychiatric disorders.
Table 2. Participant characteristics stratified by the presence and timing of diagnosis of psychiatric disorders.
VariablesTotal
(n = 37,678)		None
(n = 24,393)		Before
(n = 2288)		After
(n = 7892)		Mixed
(n = 3105)		p *
Sex <0.001
Male20,569 (54.59)12,939 (53.04) 1377 (60.18) 4334 (54.92) 1919 (61.80) -
Age at diagnosis of epilepsy <0.001
≥0 and <12 months4470 (11.86)3300 (73.83)27 (0.60)1124 (25.15)19 (0.43)-
≥12 months and <5 years6172 (15.43)4030 (65.29)308 (4.99)1487 (24.09)347 (5.62)-
≥5 and <13 years15,958 (42.35)10,763 (67.45)1124 (7.04)2759 (17.29)1312 (8.22)-
≥13 and <18 years11,078 (29.40)6300 (56.87)829 (7.48)2522 (22.77)1427 (12.88)-
Data are presented as the frequency (proportion). The shaded portion of “age at diagnosis of epilepsy” represents the proportion of the four groups at each age and shows horizontal proportions. All other data represent vertical proportions. * p-value from the chi-square test.
Table 3. Comparison of epilepsy healthcare utilization and clinical characteristics according to the presence and timing of diagnosis of psychiatric disorders.
Table 3. Comparison of epilepsy healthcare utilization and clinical characteristics according to the presence and timing of diagnosis of psychiatric disorders.
VariablesNoneBeforeAfterMixedp *
Total participants24,393 (64.74) 2288 (6.07) 7892 (20.95) 3105 (8.24)
Treatment duration (years)5.36 ± 3.59 5.59 ± 3.338.31 ± 3.656.54 ± 3.43<0.001
No. of outpatient visits39.97 ± 63.3844.72 ± 68.1480.43 ± 127.0652.09 ± 80.65<0.001
No. of ER visits2.68 ± 3.872.64 ± 4.325.39 ± 8.123.41 ± 6.69<0.001
No. of admissions3.71 ± 28.103.13 ± 18.2910.76 ± 66.103.92 ± 33.69<0.001
Total no. of medications2.31 ± 1.832.46 ± 1.934.05 ± 2.832.88 ± 2.07<0.001
Status epilepticus1354 (5.55)154 (6.73)1108 (14.04)207 (6.67)<0.001
Drug-resistant epilepsy7516 (30.81)767 (33.52)4389 (55.61)1116 (35.94)<0.001
Data are presented as the frequency (proportion) or mean ± standard deviation. Variable description: “Treatment duration” refers to the period from the index date to the date of the last medication dose. “Total no. of medications” includes the number of ASMs categorized by the ingredient name used at least once during the treatment period. “Status epilepticus” represents the number of patients diagnosed with status epilepticus at least once. “Drug-resistant epilepsy” indicates patients who have been simultaneously prescribed four or more ASMs. ASM, antiseizure medication; ER, emergency room. * p-value from the Kruskal–Wallis rank sum test.
Table 4. Logistic and Poisson regression analyses of the association of the presence and timing of diagnoses of psychiatric disorders with healthcare utilization and clinical characteristics in pediatric epilepsy (reference: None group).
Table 4. Logistic and Poisson regression analyses of the association of the presence and timing of diagnoses of psychiatric disorders with healthcare utilization and clinical characteristics in pediatric epilepsy (reference: None group).
None
(Reference)		BeforeAfterMixed
Number of outpatient visits *1.00 1.32 (1.29–1.35)2.83 (2.80–2.85)1.89 (1.85–1.93)
Number of ER visits *1.00 1.16 (1.13–1.19)2.03 (2.00–20.5)1.59 (1.56–1.63)
Number of admissions *1.00 1.32 (1.29–1.35)2.83 (2.80–2.85)1.89 (1.85–1.93)
Total number of medications *1.00 1.13 (1.10–1.16)1.76 (1.74–1.79)1.35 (1.32–1.38)
Status epilepticus +1.00 1.69 (1.41–2.01)2.92 (2.68–3.18)1.86 (1.59–2.18)
Drug-resistant epilepsy +1.00 1.34 (1.22–1.47)3.01 (2.85–3.17)1.59 (1.47–1.73)
* Poisson’s regression analysis, adjusted for sex and age; odds ratio [95% confidence interval]. + Logistic regression analysis, adjusted for sex and age; prevalence ratio [95% confidence interval]. ER, emergency room.
Table 5. Logistic and Poisson regression analyses of the association of the presence and timing of diagnoses of psychiatric disorders with clinical characteristics in pediatric epilepsy (reference: None group).
Table 5. Logistic and Poisson regression analyses of the association of the presence and timing of diagnoses of psychiatric disorders with clinical characteristics in pediatric epilepsy (reference: None group).
NoneBeforeAfterMixed
Total number of medications *0.74 (0.72–0.76)0.83 (0.81–0.86)1.30 (1.27–1.34)1.00 (Reference)
Status epilepticus +0.54 (0.46–0.63)0.91 (0.73–1.13)1.57 (1.34–1.84)1.00 (Reference)
Drug-resistant epilepsy +0.63 (0.58–0.68)0.84 (0.75–0.94)1.89 (1.73–2.06)1.00 (Reference)
* Poisson’s regression analysis, adjusted for sex and age; odds ratio [95% confidence interval]. + Logistic regression analysis, adjusted for sex and age; prevalence ratio [95% confidence interval].
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Lee, J.; Choi, A.; Kim, S. Effects of Psychiatric Comorbidities on the Prognosis of New-Onset Pediatric Epilepsy: A Retrospective Nationwide Cohort Study. J. Clin. Med. 2024, 13, 4500. https://doi.org/10.3390/jcm13154500

AMA Style

Lee J, Choi A, Kim S. Effects of Psychiatric Comorbidities on the Prognosis of New-Onset Pediatric Epilepsy: A Retrospective Nationwide Cohort Study. Journal of Clinical Medicine. 2024; 13(15):4500. https://doi.org/10.3390/jcm13154500

Chicago/Turabian Style

Lee, Jooyoung, Arum Choi, and Sukil Kim. 2024. "Effects of Psychiatric Comorbidities on the Prognosis of New-Onset Pediatric Epilepsy: A Retrospective Nationwide Cohort Study" Journal of Clinical Medicine 13, no. 15: 4500. https://doi.org/10.3390/jcm13154500

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop